The states with the highest rates of HIV diagnoses in 2022 included Georgia, Louisiana, and Florida. However, the states with the highest number of people with HIV were Texas, California, and Florida. In Texas, there were around 4,896 people diagnosed with HIV. HIV/AIDS diagnoses In 2022, there were an estimated 38,043 new HIV diagnoses in the United States, a slight increase compared to the year before. Men account for the majority of these new diagnoses. There are currently around 1.2 million people living with HIV in the United States. Deaths from HIV The death rate from HIV has decreased significantly over the past few decades. In 2023, there were only 1.3 deaths from HIV per 100,000 population, the lowest rate since the epidemic began. However, the death rate varies greatly depending on race or ethnicity, with the death rate from HIV for African Americans reaching 19.2 per 100,000 population in 2022, compared to just three deaths per 100,000 among the white population.

In 2022, the states with the highest number of HIV diagnoses were Texas, California, and Florida. That year, there were a total of around 37,601 HIV diagnoses in the United States. Of these, 4,896 were diagnosed in Texas. HIV infections have been decreasing globally for many years. In the year 2000, there were 2.8 million new infections worldwide, but this number had decreased to around 1.3 million new infections by 2023. The number of people living with HIV remains fairly steady, but the number of those that have died due to AIDS has reached some of its lowest peaks in a decade. Currently, there is no functional cure for HIV or AIDS, but improvements in therapies and treatments have enabled those living with HIV to have a much improved quality of life.

United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.500 % in 2014. This stayed constant from the previous number of 0.500 % for 2013. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.500 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.500 % in 2014 and a record low of 0.500 % in 2014. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;

This dataset contains surveillance data on diagnoses of HIV for the United States in estimates rates and numbers for Human Immunodeficiency Virus (HIV) infection diagnosis and stage 3 infection Acquired Immunodeficiency Syndrome (AIDS) as collected by the Centers for Disease Control and Prevention (CDC).

Prevalence of HIV, total (% of population ages 15-49) in United States was reported at 0.4 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. United States - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on September of 2025.

United States US: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.110 Ratio in 2019. This stayed constant from the previous number of 0.110 Ratio for 2018. United States US: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.120 Ratio from Dec 2010 (Median) to 2019, with 10 observations. The data reached an all-time high of 0.130 Ratio in 2012 and a record low of 0.110 Ratio in 2019. United States US: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

The AIDS Public Information Data Set (APIDS) for years 1981-2002 on CDC WONDER online database contains counts of AIDS (Acquired Immune Deficiency Syndrome) cases reported by state and local health departments, by demographics; location (region and selected metropolitan areas); case-definition; month/year and quarter-year of diagnosis, report, and death (if applicable); and HIV exposure group (risk factors for AIDS). Data are produced by the US Department of Health and Human Services (US DHHS), Public Health Service (PHS), Centers for Disease Control and Prevention (CDC), National Center for HIV, STD and TB Prevention (NCHSTP), Division of HIV/AIDS Prevention (DHP).

Users can access population data related to the screening, prevalence, and incidence of HIV and AIDS in the United States. Background The HIV/AIDS Statistics and Surveillance data is maintained by the Centers for Disease Control. Annual reports, fact sheets, slide sets, and basic statistics are available in a variety of formats. Fact sheets are available for a variety of subgroups including but not limited to examining HIV prevalence among different races, ages, and sexual orientations. Slide sets looking at HIV and AIDS prevalence among different groups and different regions are also available. The HIV Surveillance Report is available on an annual basis. User functionality Data is presented in report or fact sheet format and can be downloaded in PDF or HTML formats. Slide sets are available in PDF or PowerPoint format. Basic statistics and other information is avaible in HTML format. Data Notes The data sources are clearly referenced for each report, chart, and fact sheet. The most recent data is from 2009. Reports are published annually in the late summer or early fall

Rates of HIV diagnoses among adults and adolescents ages 13 and older in the US by state, 2016. Source: Centers for Disease Control and Prevention (CDC), Diagnoses of HIV infection in the United States and dependent areas, 2016. HIV surveillance report, 2017; vol 28.

This horizontal bar chart displays incidence of HIV (per 1,000 uninfected population) by capital city using the aggregation average, weighted by population in South America. The data is about countries per year.

aIncludes cases of HIV infection, newly diagnosed in Australia in 2010 and reported by 31 March 2012. The exposure category “Heterosexual contact” includes cases from high prevalence countries in sub-Saharan Africa and specific countries in South East Asia (Burma, Cambodia).bDataset is not nationally representative; it includes data from 5 of the 13 provinces and territories. Across all 13 provinces and territories, a total of 2,358 HIV cases were reported in 2010. The case definition for AIDS in Canada is based on confirmed HIV diagnosis and presence/diagnosis of an AIDS-defining condition (no criteria for CD4 count are included in Canada’s AIDS case definition).cData for the whole country, adjusted for under-reporting and reporting delays. Missing data on age,sex, transmission category and clinical stage are imputed. Data reported as of 30 June, 2011. MSM-IDU are in “others”.dIn 2010 the coverage of HIV surveillance system is 97.8%. AIDS is undereported. AIDS defined as clinical stage C (CDC classification).eIncludes cases of HIV infection, newly diagnosed in the United States in 2010 and reported by 31 December 2011. Estimated numbers resulted from statistical adjustment that accounted for missing risk-factor information, but not for reporting delays and incomplete reporting.fMSM, men who have sex with men; IDU, injection drug use.

United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data was reported at 0.020 % in 2014. This stayed constant from the previous number of 0.020 % for 2013. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data is updated yearly, averaging 0.030 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.030 % in 2012 and a record low of 0.020 % in 2014. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 100 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted Average;

The Housing Opportunities for Persons with AIDS (HOPWA) program funds are distributed to states and cities by formula allocations and made available as part of the area's Consolidated Plan. Persons living with HIV/AIDS and their families may require housing that provides emergency, transitional, or long-term affordable solutions. In addition, some projects are selected in national competitions to serve as service delivery models or operate in non-formula areas. Grantees partner with nonprofit organizations and housing agencies to provide housing and support to beneficiaries.

To learn more about the HOPWA program visit: https://portal.hud.gov/hudportal/HUD?src=/program_offices/comm_planning/aidshousing, for questions about the spatial attribution of this dataset, please reach out to us at GISHelpdesk@hud.gov. Data Dictionary: DD_HOPWA Grantee Areas

Date of Coverage: FY 2024 Data Updated: Annually

The Find Ryan White HIV/AIDS Medical Care Providers tool is a locator that helps people living with HIV/AIDS access medical care and related services. Users can search for Ryan White-funded medical care providers near a specific complete address, city and state, state and county, or ZIP code. Search results are sorted by distance away and include the Ryan White HIV/AIDS facility name, address, approximate distance from the search point, telephone number, website address, and a link for driving directions. HRSA's Ryan White program funds an array of grants at the state and local levels in areas where most needed. These grants provide medical and support services to more than a half million people who otherwise would be unable to afford care.

HIV/AIDS data from the HIV Surveillance Annual Report
* Note: Data reported to the HIV Epidemiology and Field Services Program by June 30, 2016. All data shown are for people ages 13 and older. Borough-wide and citywide totals may include cases assigned to a borough with an unknown UHF or assigned to NYC with an unknown borough, respectively. Therefore, UHF totals may not sum to borough totals and borough totals may not sum to citywide totals."

The HIV Testing Sites & Care Services Locator is a first-of-its-kind, location-based search tool that allows you to search for testing services, housing providers, health centers and other service providers near your current location.

*Aged 13 and older in ASD and the US living HIV/AIDS cases, 18 and older in SHAS†Estimated number of persons living with HIV/AIDS at the end of 2003 from 33 areas with confidential name-based HIV infection reporting‡Not available: data on patients with Hispanic ethnicity are not reported in cohort profile [40]

All figures are given as % (95% CI) unless noted. There were 61 counties in the top decile and 551 in the remaining deciles.

BackgroundThe risks of HIV transmission associated with the opioid epidemic make cost-effective programs for people who inject drugs (PWID) a public health priority. Some of these programs have benefits beyond prevention of HIV—a critical consideration given that injection drug use is increasing across most United States demographic groups. To identify high-value HIV prevention program portfolios for US PWID, we consider combinations of four interventions with demonstrated efficacy: opioid agonist therapy (OAT), needle and syringe programs (NSPs), HIV testing and treatment (Test & Treat), and oral HIV pre-exposure prophylaxis (PrEP).Methods and findingsWe adapted an empirically calibrated dynamic compartmental model and used it to assess the discounted costs (in 2015 US dollars), health outcomes (HIV infections averted, change in HIV prevalence, and discounted quality-adjusted life years [QALYs]), and incremental cost-effectiveness ratios (ICERs) of the four prevention programs, considered singly and in combination over a 20-y time horizon. We obtained epidemiologic, economic, and health utility parameter estimates from the literature, previously published models, and expert opinion. We estimate that expansions of OAT, NSPs, and Test & Treat implemented singly up to 50% coverage levels can be cost-effective relative to the next highest coverage level (low, medium, and high at 40%, 45%, and 50%, respectively) and that OAT, which we assume to have immediate and direct health benefits for the individual, has the potential to be the highest value investment, even under scenarios where it prevents fewer infections than other programs. Although a model-based analysis can provide only estimates of health outcomes, we project that, over 20 y, 50% coverage with OAT could avert up to 22,000 (95% CI: 5,200, 46,000) infections and cost US$18,000 (95% CI: US$14,000, US$24,000) per QALY gained, 50% NSP coverage could avert up to 35,000 (95% CI: 8,900, 43,000) infections and cost US$25,000 (95% CI: US$7,000, US$76,000) per QALY gained, 50% Test & Treat coverage could avert up to 6,700 (95% CI: 1,200, 16,000) infections and cost US$27,000 (95% CI: US$15,000, US$48,000) per QALY gained, and 50% PrEP coverage could avert up to 37,000 (22,000, 58,000) infections and cost US$300,000 (95% CI: US$162,000, US$667,000) per QALY gained. When coverage expansions are allowed to include combined investment with other programs and are compared to the next best intervention, the model projects that scaling OAT coverage up to 50%, then scaling NSP coverage to 50%, then scaling Test & Treat coverage to 50% can be cost-effective, with each coverage expansion having the potential to cost less than US$50,000 per QALY gained relative to the next best portfolio. In probabilistic sensitivity analyses, 59% of portfolios prioritized the addition of OAT and 41% prioritized the addition of NSPs, while PrEP was not likely to be a priority nor a cost-effective addition. Our findings are intended to be illustrative, as data on achievable coverage are limited and, in practice, the expansion scenarios considered may exceed feasible levels. We assumed independence of interventions and constant returns to scale. Extensive sensitivity analyses allowed us to assess parameter sensitivity, but the use of a dynamic compartmental model limited the exploration of structural sensitivities.ConclusionsWe estimate that OAT, NSPs, and Test & Treat, implemented singly or in combination, have the potential to effectively and cost-effectively prevent HIV in US PWID. PrEP is not likely to be cost-effective in this population, based on the scenarios we evaluated. While local budgets or policy may constrain feasible coverage levels for the various interventions, our findings suggest that investments in combined prevention programs can substantially reduce HIV transmission and improve health outcomes among PWID.

BackgroundIn the generalised epidemics of sub-Saharan Africa (SSA), human immunodeficiency virus (HIV) prevalence shows patterns of clustered micro-epidemics. We mapped and characterised these high-prevalence areas for young adults (15–29 years of age), as a proxy for areas with high levels of transmission, for 7 countries in Eastern and Southern Africa: Kenya, Malawi, Mozambique, Tanzania, Uganda, Zambia, and Zimbabwe.Methods and findingsWe used geolocated survey data from the most recent United States Agency for International Development (USAID) demographic and health surveys (DHSs) and AIDS indicator surveys (AISs) (collected between 2008–2009 and 2015–2016), which included about 113,000 adults—of which there were about 53,000 young adults (27,000 women, 28,000 men)—from over 3,500 sample locations. First, ordinary kriging was applied to predict HIV prevalence at unmeasured locations. Second, we explored to what extent behavioural, socioeconomic, and environmental factors explain HIV prevalence at the individual- and sample-location level, by developing a series of multilevel multivariable logistic regression models and geospatially visualising unexplained model heterogeneity. National-level HIV prevalence for young adults ranged from 2.2% in Tanzania to 7.7% in Mozambique. However, at the subnational level, we found areas with prevalence among young adults as high as 11% or 15% alternating with areas with prevalence between 0% and 2%, suggesting the existence of areas with high levels of transmission Overall, 15.6% of heterogeneity could be explained by an interplay of known behavioural, socioeconomic, and environmental factors. Maps of the interpolated random effect estimates show that environmental variables, representing indicators of economic activity, were most powerful in explaining high-prevalence areas. Main study limitations were the inability to infer causality due to the cross-sectional nature of the surveys and the likely under-sampling of key populations in the surveys.ConclusionsWe found that, among young adults, micro-epidemics of relatively high HIV prevalence alternate with areas of very low prevalence, clearly illustrating the existence of areas with high levels of transmission. These areas are partially characterised by high economic activity, relatively high socioeconomic status, and risky sexual behaviour. Localised HIV prevention interventions specifically tailored to the populations at risk will be essential to curb transmission. More fine-scale geospatial mapping of key populations,—such as sex workers and migrant populations—could help us further understand the drivers of these areas with high levels of transmission and help us determine how they fuel the generalised epidemics in SSA.